Herceptin Market - By Product, By Application, By Route of Administration, By Distribution Channel & Global Forecast, 2025 - 2034

Herceptin Market Size

The global herceptin market size was estimated at USD 3.3 billion in 2024. The market is expected to grow from 3.4 billion in 2025 to 5.5 billion in 2034, at a CAGR of 5.4% during the forecast period. The Herceptin also known as trastuzumab, a medicine mainly used to treat HER2-positive breast cancer. This drug helps to block the protein HER2 which makes cancer grow faster. Herceptin works by targeting and blocking this protein, stopping the cancer from growing and spreading.
 

The market is growing rapidly, stimulated by some major growth factors. One of the key catalyst is the increasing number of HER2-positive breast cancer cases. This type of breast cancer occurs when the tumor cells produce too much of a protein called HER2 (Human Epidermal growth factor Receptor 2). Having more HER2 makes the cancer more aggressive and harder to treat with traditional methods. Because of this, there has been a growing need for targeted therapies such as Herceptin (trastuzumab).
 

Herceptin works by specifically targeting and blocking the HER2 protein, helping slow down the cancer's growth and improve patient’s outcomes. This shift towards more precise treatments is  accelerating the demand for Herceptin and similar therapies.
 

For instance, in February 2024, the World Health Organization (WHO) reported that in 2022, around 2.3 million women worldwide were diagnosed with breast cancer, making it the most common cancer among women, of these diagnosed cases, 15-20% are HER2-positive, a more aggressive type of breast cancer wherein the cancer cells produce too much of the HER2 protein. This makes the cancer harder to treat, underlining the urgent need for treatments that are specifically designed to target this more difficult form of breast cancer.
 

Therefore, as more people diagnosed with HER2-positive breast cancer, the demand for targeted treatments such as Herceptin (trastuzumab) is anticipated to grow. Moreover, Herceptin has proven to be a game-changer, especially when used in combination with chemotherapy or other therapies, whether for early-stage or metastatic breast cancer. By specifically targeting the cancer, it has significantly improved survival rates, offering new hope to many woman battling this aggressive form of the disease.
 

Herceptin Market Trends

• The market is growing rapidly fuelled by factors, such as the rising number of HER2-positive breast cancer cases in various countries. For instance, as per the 2021 report by the UK Government, approximately 92,620 cases of HER2-positive breast cancer occur annually in the European Union.
   
• This growing incidence of HER2-positive breast cancer has led to an increased demand for targeted treatments such as Herceptin, which plays a critical role in improving patient outcomes.
   
• Moreover, the market is also benefiting from the expiration of the trastuzumab patent in the developed regions such as  Europe and the U.S. Due to this several trastuzumab biosimilars got the chance to enter the market, which are identical to the original Herceptin.
   
• These biosimilars have showed great results and are also making the treatment more accessible and affordable, especially in emerging markets where the high price of the original Herceptin had previously been a major barrier. By providing a more affordable alternative without compromising the effectiveness, these biosimilars are ensuring that more women have the chance to receive the life-saving treatment they need.
   
• Additionally, now a days more people and healthcare systems in the emerging countries are becoming aware of HER2-positive breast cancer and the treatments that are available, new combination therapies are being developed that are making a real difference in improving survival rates for patients.
   
• Therefore, as more healthcare systems and patients across the globe start to utilize this innovative treatment, the market is set to keep developing.
   

Trump Administration Tariffs

• The Trump administrations tariffs on imports from China, which include pharmaceutical grade polymer powders and equipment used in biopharmaceutical processing, may exacerbate the cost of manufacturing Herceptin and its biosimilars. Considering that a large portion of the raw materials, active pharmaceutical ingredients (APIs), and intricate manufacturing systems are either procured or manufactured in China, the tariffs might increase the cost of production and strain supply chains.
   
• Consequently, the biopharmaceutical firms participating in the herceptin market may rethink their global sourcing approaches. This might provide impetus for an incremental transition to sourcing from India, South Korea, and some parts of Europe that possess well developed biopharma infrastructure and regulatory systems.
   
• In the intermediate term, the tariffs may cause additional delays in production schedules, reimbursement expenses associated with vendor and logistics, and maintaining supply constancy for Herceptin and its biosimilars. These supply shifts may change pricing and contracting strategies for healthcare services and insurance companies.
   

Herceptin Market Analysis

Based on the product, the market is segmented into biologic and biosimilars. The market was estimated at USD 3.1 billion in 2023. The biosimilar segment held revenue of USD 1.7 billion in 2024, and the segment is poised for significant growth at a CAGR of 5.6% during the forecast period.
 

• This expansion is stimulated due to the expiration of the Herceptin patent and the increasing adoption of biosimilars, which are more affordable alternatives to the original Herceptin.
   
• These biosimilars have demonstrated similar clinical efficacy to the originator drug in several clinical trials, offering more accessible treatment options to patients, particularly in emerging markets where the original Herceptin may have been prohibitively expensive.
   
• Additionally, the growth of the biosimilar segment is further stimulated by a global shift to reduce healthcare costs, particularly in cancer diagnostics, which is estimated to reach USD 372.5 billion by 2034, and treatment.
   
• With the approval of several trastuzumab biosimilars, such as Ogivri, Herzuma, and Ontruzant, has provided hospitals and healthcare providers with more affordable options compared to the original Herceptin, which is making a huge difference, as more women with HER2-positive breast cancer are able to access the life-saving treatment they need without the financial burden that often comes with expensive therapies.

Based on application, the herceptin market is segmented into breast cancer and stomach/gastric cancer. Breast cancer segment held a revenue share of 60.2% in 2024 and is projected for significant growth to reach USD 3.2 billion by 2034.
 

• Breast cancer is observed to be the most common cancer diagnosed in women globally and the numbers keep rising each year. The World Health Organization (WHO) in 2022 reported that breast cancer caused 670,000 deaths globally, making it the leading cause of cancer-related deaths among women.
   
• Moreover, it is observed that around 0.5 – 1% of breast cancer cases also occur in men. These statistics shows the urgent need for more advanced and targeted treatments such as Herceptin. Herceptin has become a vital treatment option for the individuals battling with HER2-positive breast cancer, which is a more aggressive form of breast cancer.
   
• Herceptin has had influence in lives of numerous ladies by helping them to live longer, with a minimal chance of the cancer recurrence, and has improved their overall quality of life.
   
• Therefore, as the prevalence of breast cancer increases among the women so does the need for effective treatment option such as Herceptin, thereby positively influencing the segmental growth.
   

Based on the route of administration, the herceptin market is segmented into intravenous (IV) and subcutaneous (SC). The IV segment held a revenue share of 69.2% in 2024 and is projected for significant growth to reach USD 3.9 billion by 2034.
 

• This growth is primarily attributed to the widespread adoption of IV administration in oncology treatments due to its rapid onset of action, higher bioavailability, and suitability for delivering high-dose medications.
   
• In 2021, according to PubMed, the IV route of administration made up a major contributor of all Herceptin treatments reflecting a significant number of treatment cycles. This shows the importance of the IV route of administration in the fight against HER2-positive breast cancer.
   
• Whereas the IV route remains the most common method for administering Herceptin, the SC route of administration is also rapidly increasing in popularity.
   
• The SC route of administration offers many benefits such as, including a faster infusion time and the comfort of being administered outside of a hospital setting that makes the treatment simpler for patients, improving their compliance, and the lower healthcare costs.
   
• Therefore, as more individuals realize the advantages of the SC route of administration, its anticipated to grow in use, giving more flexible alternatives for patients and healthcare providers.
   

Based on distribution channel, the herceptin market is segmented into hospital pharmacies, speciality pharmacies, and online pharmacies. The hospital pharmacies segment accounted for a 52.2% market share in 2024.
 

• The dominance of this segment is mostly attributed due to specialized care provided in hospital settings. Hospital pharmacies play a crucial role in ensuring that Herceptin and its biosimilar drugs are accessible and securely managed, especially for newly diagnosed patients or those with more complex conditions that require careful monitoring and close medical attention.
   
• Hospital pharmacies educate patients about the medications, their potential side effects, and the correct way to use them and also ensures that patients have access to Herceptin and its biosimilars. With personalized counselling, they help patients understand the differences between the various formulations, making sure they feel confident and informed about their treatment.
   
• In addition, these pharmacies provide valuable services such as patient support programs, medication management, and close monitoring of the way patients are responding to treatment. By working closely with healthcare professionals, they help improve patient adherence to prescribed therapies, ultimately boosting treatment outcomes and supporting the growth of the market.

The U.S. herceptin market is forecasted to reach USD 2.2 billion by 2034.
 

• The availability of highly skilled healthcare professionals with specialization in women’s health and gynecology is significantly contributing to the market growth in the country. OB/GYNs play a significant role across the spectrum of cancer awareness, from cervical and endometrial cancers to breast cancer.
   
• For instance, in May 2022, the U.S. Bureau of Labor Statistics reported that there were around 19,820 obstetricians and gynecologists within the nation.
   
• This devoted bunch of healthcare experts plays a crucial part in spreading awareness and managing the rising number of cancer cases among women. Their work is essential in stimulating the developing demand for targeted treatments such as Herceptin in the country.
   

Europe: The herceptin market in the UK is projected to grow significantly from 2025 to 2034.
 

• The country’s well set up healthcare framework and the widespread access to advanced cancer treatments ensures that woman diagnosed with HER2-positive breast cancer have access to cutting-edge medications, stimulating the adoption  of Herceptin within the nation.
   
• In UK, as per the estimates a woman is diagnosed with breast cancer every 10 minutes, and a man every day. With breast cancer being the foremost common cancer in the UK, making up 15% of all new cases. This alarming statistic underscores the expanding requirement for targeted medications such as Herceptin.
   
• Therefore, as UK proceeding to prioritize access to high-quality healthcare and cutting-edge treatments, the request for Herceptin is likely to rise even further within the future.
   

Asia Pacific: The herceptin market in the Japan is projected to grow significantly from 2025 to 2034.
 

• In Japan, the number of breast cancer diagnoses has been expanding consistently, with breast cancer presently being the foremost common cancer among women. In 2021,according to Statista, around 101,000 new cases were reported in the country which truly highlights the developing requirement for viable treatments such as Herceptin.
   
• Moreover, Japan’s strong healthcare framework, combined with the government's commitment to improving access to advanced treatments, has made it simpler for more patients to access medications such as Herceptin, thereby propelling the market growth in the region.
   

Middle East and Africa: The herceptin market in Saudi Arabia is projected to grow significantly from 2025 to 2034.
 

• The development of the market is being strongly stimulated by expanding investments in healthcare framework, especially in advanced cancer treatments such as Herceptin and its biosimilars. These investments are essentially boosting the market's development in the country.
   
• For instance, Saudi Arabia's Vision 2030 involves major investments in healthcare infrastructure, aimed at improving the quality and accessibility of medical services, including cancer treatment.
   
• This push is expected to enhance the availability of advanced cancer care, positioning the country as a key player in the Middle East and Africa's healthcare landscape.
   

Herceptin Market Companies

The market is competitive, having both the newer players and the established pharmaceutical companies working to offer better treatment options and biosimilars. Major companies such as Herceptin, the first developer of Genentech, hold a noteworthy portion of the market, alongside with Mylan N.V., Celltrion Healthcare, Samsung Bioepis, and Pfizer.
 

Together, these top 4 key players account for a market share of approximately 40% in the market. These companies are intensely contributing to research and development, to remain at the forefront, aiming to enhance the effectiveness and safety of Herceptin and its biosimilars. Their progressing efforts incorporate clinical trials to assess new combinations and dose forms, as well as exploring potential uses beyond breast cancer, such as in gastric cancer. These progressions are helping to ensure better results for patients with HER2-positive breast cancer and making the treatment alternatives accessible to them, enabling market players to strengthen their position in this growing sector.
 

Herceptin Market Companies

Some of the eminent market participants operating in the herceptin industry include:

• Amgen
• AryoGen Pharmed
• Biocon
• Celltrion Healthcare
• Dr. Reddy’s Laboratories
• Genentech
• Mylan N.V.
• Pfizer
• Samsung Bioepis
• Sandoz
• Shanghai Henlius Biotech
• Amgen has a strong global presence, with its products being sold in more than 100 countries.
• Sandoz, a division of Novartis, is one of the global leaders in biosimilars, with a broad portfolio of oncology products.
   

Herceptin Industry News:

• In January 2025, AstraZeneca announced that its drug Enhertu (trastuzumab deruxtecan) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-positive breast cancer following prior treatment with trastuzumab-based therapy. This approval enhanced AstraZeneca's portfolio in oncology, providing a critical treatment option for patients and strengthened the company's competitive position in the breast cancer therapeutics market.
   
• In March 2024, Accord BioPharma announced the approval of a 420mg strength of Hercessi (trastuzumab-strf), a biosimilar of Herceptin by the U.S. Food and Drug Administration (FDA). This approval provided a more flexible dosing option for the treatment of several forms of HER2-overexpressing cancers, helped to improve patient care and treatment efficiency, while strengthening the company’s position in the growing biosimilars market.
   

The herceptin market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Biologic
• Biosimilars

Market, By Application

• Breast cancer
• Stomach/gastric cancer

Market, By Route of Administration

• Intravenous
• Subcutaneous

Market, By Distribution Channel
 

• Hospitals pharmacies
• Specialty pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE